These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21949697)

  • 1. Characterisation of genome-wide PLZF/RARA target genes.
    Spicuglia S; Vincent-Fabert C; Benoukraf T; Tibéri G; Saurin AJ; Zacarias-Cabeza J; Grimwade D; Mills K; Calmels B; Bertucci F; Sieweke M; Ferrier P; Duprez E
    PLoS One; 2011; 6(9):e24176. PubMed ID: 21949697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
    Rice KL; Hormaeche I; Doulatov S; Flatow JM; Grimwade D; Mills KI; Leiva M; Ablain J; Ambardekar C; McConnell MJ; Dick JE; Licht JD
    Blood; 2009 Dec; 114(27):5499-511. PubMed ID: 19855079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
    Yang WC; Shih HM
    Oncogene; 2013 Oct; 32(43):5167-75. PubMed ID: 23208507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements.
    Sainty D; Liso V; Cantù-Rajnoldi A; Head D; Mozziconacci MJ; Arnoulet C; Benattar L; Fenu S; Mancini M; Duchayne E; Mahon FX; Gutierrez N; Birg F; Biondi A; Grimwade D; Lafage-Pochitaloff M; Hagemeijer A; Flandrin G; ; ; ;
    Blood; 2000 Aug; 96(4):1287-96. PubMed ID: 10942370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.
    Guidez F; Parks S; Wong H; Jovanovic JV; Mays A; Gilkes AF; Mills KI; Guillemin MC; Hobbs RM; Pandolfi PP; de Thé H; Solomon E; Grimwade D
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18694-9. PubMed ID: 18000064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
    Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
    Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
    Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.
    Girard N; Tremblay M; Humbert M; Grondin B; Haman A; Labrecque J; Chen B; Chen Z; Chen SJ; Hoang T
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13522-7. PubMed ID: 23898169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
    Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
    Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression.
    McConnell MJ; Chevallier N; Berkofsky-Fessler W; Giltnane JM; Malani RB; Staudt LM; Licht JD
    Mol Cell Biol; 2003 Dec; 23(24):9375-88. PubMed ID: 14645547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two critical hits for promyelocytic leukemia.
    He LZ; Bhaumik M; Tribioli C; Rego EM; Ivins S; Zelent A; Pandolfi PP
    Mol Cell; 2000 Nov; 6(5):1131-41. PubMed ID: 11106752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
    He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
    Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein.
    Li JY; English MA; Ball HJ; Yeyati PL; Waxman S; Licht JD
    J Biol Chem; 1997 Sep; 272(36):22447-55. PubMed ID: 9278395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
    Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
    Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha oncoprotein.
    Tsuzuki S; Enver T
    Blood; 2002 May; 99(9):3404-10. PubMed ID: 11964310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A.
    Yeyati PL; Shaknovich R; Boterashvili S; Li J; Ball HJ; Waxman S; Nason-Burchenal K; Dmitrovsky E; Zelent A; Licht JD
    Oncogene; 1999 Jan; 18(4):925-34. PubMed ID: 10023668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor.
    Ward JO; McConnell MJ; Carlile GW; Pandolfi PP; Licht JD; Freedman LP
    Blood; 2001 Dec; 98(12):3290-300. PubMed ID: 11719366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.